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Abstract We analyze how a manufacturer with a brand-name drug close to patent
expiration decides to launch a product-line extension (an upgrade through innovation)
before it faces generic competition. There are two types of physicians: loyal physicians
always prescribe first the product-line extension and then either the off-patent drug or
a generic drug while the non-loyal ones prescribe taking into account the prices of the
drugs. We consider a two-stage game. In the first stage, the incumbent firm decides
the level of innovation. In the second-stage, all firms decide sequentially their prices,
with the incumbent firm acting as a Stackelberg leader. We find two equilibria in the
pricing-decision game. For relatively large levels of innovation, the incumbent firm
competes for the price-sensitive physicians. However, for low levels of innovation,
the incumbent firm prefers to exploit the loyal physicians and to charge the monopoly
price. The equilibrium level of innovation exhibits an inverted U-shaped behaviour
with respect to the degree of loyalty.
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1 Introduction
When brand-name drugs go off patent, they face generic competition. Historically,
pharmaceutical firms have been able to maintain high prices after patent-expiration
due to the existence of barriers to entry. During the eighties, new legislation to over-
come entry barriers in pharmaceutical markets was enacted in the European Union and
the US. In particular, the 1984 Drug Price Competition and Patent Term Restoration
Act eased market entry for generic drugs as they only needed to prove bioequivalence
to the brand-name drugs. Since then, the number of generic drugs entering the market
has been continuously growing.
The economic literature has mainly focused on analyzing the effect of generic entry
in the prices of brand-name drugs. However, less attention (specially from a theoretical
perspective) has been paid to other strategies that pharmaceutical firms can use to cope
with generic competition and protect their market shares and revenues. In particular,
brand-name drug firms can limit generic entry by launching the so called ‘pseudog-
enerics’ (Kong 2009) or even by taking over generic firms (European Commision
2009). Alternatively, pharmaceutical firms can launch product-line extensions (Hong
et al. 2005). A line extension is a variation of an existing product or a modification of
an existing molecular entity. This strategy allows brand-name drug firms extend the
original drug with a new modification, and shifts demand from the original brand to the
new extension. These line extensions of off-patent drugs allow the firm to introduce
a differentiated product to compete with the generic drugs, and they often substitute
for the original drug.1
Product line extensions require, compared to blockbuster drugs, lower R&D expen-
ditures.2 According to global figures, most of the new drugs are not based on really
new chemical ingredients. Grabowski and Wang (2006) reported that worldwide and
for the period 1982–2003, 919 new chemical ingredients were introduced, being only
115 of them first in class, i.e. strictly new.3 Hong et al. (2005) report that only 15% of
the 1,035 new drugs approved by the US Food and Drug Administration from 1989
through 2000 were innovative drugs. In Spain, according to the Ministry of Health and
Consumption (2005), 782 new specialities were registered in 2004, from which 747
were based in already known chemical ingredients (about 300 were generic drugs) and
35 in new ones. These figures indicate that new drugs (new registered products with
their corresponding patents) come basically from developments of known chemical
1 According to a recent classification for drug innovations suggested by Caprino and Russo (2006), product-
line extensions could be considered as type D (new chemical ingredients structurally related to a chemical
class already described for a similar therapeutic indication); type E (known pharmaceutical products gener-
ated through biotechnology or other very innovative techniques); type F (known pharmaceutical products
with either new characteristics or more relevance due to its pharmaceutical form or administration path)
and type G (known pharmaceutical products that have new characteristics or that have less relevance due
to its pharmaceutical form, administration path, safety or handling improvements).
2 DiMasi et al. (2003) found a cost of over 800 million US dollars to produce a new pharmaceutical product,
including the whole R&D process to discover the new chemical ingredient.
3 Among the 804 minor innovations, there are also follow-on drugs produced by competing firms and prod-
uct-line extensions (upgrades) produced by leading firms. New registered drugs based on minor innovations
overwhelmingly exceed new first-in-class drugs.
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ingredients and only a low proportion (less than 5% in Spain) are derived from really
new ones.
The pharmaceutical industry seems to have opted for the strategy of introducing
new drugs based on minor innovations (upgrades and product-line extensions). The
new drug is usually protected by additional periods of patent exclusivity.4 The original
drug, the new product (line-extension) and the generics may coexist in the market.
In this paper, we consider a manufacturer of a brand-name drug close to patent expi-
ration that must decide whether to introduce a product-line extension (upgrade) of the
existing brand-name drug to cope with generic competition. Specifically, we focus on
the situation of a leading firm that produces a successful drug (a star product) with
high loyalty from prescribers and close to patent expiration. The firm can, of course,
try to get another first-in-class drug after a long and expensive R&D process. How-
ever, the firm can also take advantage of brand-loyalty and, with low R&D expenses,
obtain a new differentiated product (through a minor innovation, upgrading or just
designing a line extension) before generic drugs similar to the off-patent drug enter
the market and price competition takes place. This situation is frequently observed
when the off-patent drug has been very successful in the market.5
To simplify the analysis, we assume that the outcome of R&D expenditures is deter-
ministic, and that there is free pricing for new drugs.6 We consider a standard model
of vertical product differentiation where the incumbent firm faces the competition of
n generic drug firms. The demand for drugs is determined by physicians. We con-
sider that there are two types of doctors. On the one hand, a proportion of physicians
prefers the innovative drug and prescribes it first as long as the patient’s net utility is
non-negative. In case the line extension prescription causes negative net utility to a
patient, these doctors may prescribe her either the off-patent drug or any of the avail-
able generic drugs. Throughout the paper, we call these doctors “loyal” physicians.
These physicians prefers the new drug produced by the incumbent firm to any other
drug available. Here, loyalty means that these physicians always prescribe the line
extension regardless of the prices as long as the patient’s net utility is non-negative.
They remain loyal to the firm that initially developed the off-patent drug, and now, they
prefer first to prescribe the upgraded drug (the line extension) produced by the same
firm. On the other hand, the remaining physicians base their prescribing decisions on
efficiency considerations and take into account both the effectiveness and the prices
of the drugs.
4 When the line-extension is based on a new chemical entity, it is always granted patent protection. However,
it may be the case that slight modifications of existing drugs are not protected by a patent or are protected by
weak patents. Manufacturers of line-extensions seek the highest protection for their new product through a
patent to replace sales lost when the original drug goes off patent.
5 For instance, the firm Lundbeck that produced “citalopram”, a band-name drug for moderate–severe
depression with patent protection, developed, before patent expiration, a minor innovation “escitalopram”
to reduce the immediate generic competition.
6 In European countries, pharmaceutical markets are highly regulated, and reference pricing systems are
used. Our model considers free pricing, and therefore it is better applied to a situation like the US market.
See the conclusion section for some comments on how our results might change if a reference pricing
system is in place.
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We model the interaction between firms as a two-stage game. In the first stage, the
producer of the brand-name drug decides the degree of product differentiation through
innovation. In the second stage, firms sequentially set their prices. We assume that the
producer of the brand-name drug acts as a Stackelberg leader in the pricing game.
Brand-name drug firms often introduce the line extension previously to the generic
entry to shift demand through brand-loyalty. So, the choice of Stackelberg leadership
seems to be a good approximation to real world.
Our goal is to characterize the equilibrium prices and the equilibrium level of inno-
vation. We also analyze how both the equilibrium level of innovation and the sales of
generic drugs behave when the proportion of loyal physicians changes. We find that,
for a sufficiently high proportion of loyal physicians, the equilibrium price of the line
extension is such that the line extension is only prescribed by the loyal physicians.
When the proportion of loyal physicians is low, however, both type of physicians pre-
scribe in equilibrium the line extension. We also find that the higher the proportion
of price-sensitive physicians, the larger the sales of generic drugs are. Regarding the
level of innovation, we find that the equilibrium level of innovation exhibits an inverted
U-shaped behavior with respect to the proportion of loyal physicians: it increases when
this proportion is low and decreases when it is high. From a social welfare perspective,
the level of innovation chosen by the firm is too low. When the proportion of loyal
physicians is relatively high, it seems to be desirable to reduce it. The level of inno-
vation would be higher as well as the social welfare. Health authorities could act on
detailing as, after all, pharmaceutical firms rely on this marketing activity to generate
loyalty to their products.
Our paper contributes to the theoretical literature of pharmaceutical markets and
generic competition. Theoretical analysis of competition in pharmaceutical markets
began with the seminal paper by Frank and Salkever (1992). They focused on ana-
lyzing the effect of generic competition on the prices of off-patent drugs to explain
the puzzling increase in the prices of brand-name drugs after generic entry (‘Generic
Competition Paradox’). They concluded that one possible explanation was that generic
entry could make the demand of brand-name drugs steeper. (See also Lexchin 2004;
Regan 2008; Mestre 1999; Kong 2009; Ferrara and Kong 2008 for alternative expla-
nations of the ‘Generic Competition Paradox’.) Innovation in pharmaceutical markets
has been recently analyzed by Bardey et al. (2010). They focus on how reference
pricing affects the type of innovations brought to the market, but they do not ana-
lyze the relationship between innovation and generic entry. Another strand of research
has focused on advertising as the mechanism by which pharmaceutical firms try to
influence the prescribing behavior of physicians. (See Königbauer 2006, 2007) These
papers endogenize the proportion of price-sensitive physicians by determining the
optimal level of advertising expenditures, leaving as exogenous the level of product
differentiation (the quality of the brand-name and the generic drug). On the contrary,
our paper takes as exogenous the proportion of price-sensitive physicians and endog-
enizes the degree of product differentiation through innovation. Finally, other papers
(Brekke et al. 2007; Cabrales 2003; Kyle 2007; Ekelund and Peersson 2003; Dalen et
al. 2006; Danzon and Chao 2000) have analyzed the effects of market regulation in
drug prices. To the best of our knowledge, our paper is the first attempt to analyze, from
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a theoretical perspective, the role that product-line extensions play in pharmaceutical
markets following generic entry.
The paper is structured as follows. Section 2 describes the model, and in Sect. 3,
the equilibrium prices are determined. Section 4 characterizes the equilibrium level of
innovation, and analyses its behavior with the proportion of brand-loyal physicians,
variable through which public policy can influence prescription in our model. In Sect. 5,
welfare analysis is carried out and public policy considerations are described. Finally,
conclusions are presented in Sect. 6.
2 The model
We consider a standard model of vertical product differentiation applied to pharma-
ceuticals markets.7 There are n+1 firms where firm 1 is the incumbent firm producing
a brand-name drug and a line extension while the remaining n firms produce generic
drugs. Firm 1 faces patent expiration for its brand-name prescription drug and must
decide the degree of product differentiation through innovation for its new drug (a line
extension) before n firms enter the market with generic drugs.
There is a continuum of consumers (patients) with the same illness that can be
treated with either of the three drugs.8 Consumers are indexed by θ , which is uni-
formly distributed in the interval [0, 1] with density one. The parameter θ measures
the severity of the illness. Each consumer is assumed to buy (to be prescribed) at most,
one unit of the product (drug). In the case of drugs, patients do not choose directly
the drug but this is, instead, prescribed by physicians. So, the demand for drugs is
determined by physicians. We assume that there is a population of physicians of size
one. Physicians, when they treat a patient, observe the parameter θ and decide which
drug to prescribe. Let si be the quality of the good (drug) from firm i perceived by
all physicians, i ∈ {1, 2, . . . , n + 1}. Perceived quality is a combination of baseline
and innovative attributes, such that we can write si = fi + ki , where fi and ki denote
respectively the baseline and innovative attributes of the drug produced by firm i . From
the physicians perspective, patients’ utility depends on the severity of their illness and
on the prescribed drug so that we can write θsi as the gross utility that a patient with
a severity of illness θ obtains when she is prescribed the good (drug) from firm i .9
All drugs have the same baseline attribute, fi = f ∀i , but only firm 1 produces a
drug (the line extension) with the innovative attribute: k1 = k and ki = 0 for i = 1
For the sake of simplicity and without loss of generality, we will assume that f = 1.
Firm 1 can produce the innovative attribute k ≥ 0 at a cost C(k), with C(0) = 0,
C ′(k) > 0, C ′′(k) > 0 and C ′(0) = 0. To simplify the analysis, we assume that mar-
ginal production costs for all firms and drugs are zero. The line extension is assumed
to be protected by the patent system.
7 See Gabszewicz and Thisse (1979), Mussa and Rosen (1978) and Shaked and Sutton (1982) for standard
product differentiation models.
8 Throughout the paper, we use the terms consumers and patients interchangeably.
9 The parameter θ can be also interpreted as the patients’ marginal valuation for quality.
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Among the population of physicians, a proportion α ∈ (0, 1) consists of physicians
who take only into account the innovative attribute, and therefore, they prescribe first
the drug with the highest perceived innovative quality (the line extension) regardless
of its price as long as the patients’ net utility is non-negative.10 Type α physicians also
consider that the off-patent drug is therapeutically equivalent to the generic drugs.
For patients whose net utility was negative if they were prescribed the line extension,
these physicians may prescribe either the off-patent or a generic drug. The off-patent
drug and the generic drugs have the same chemical entity. In some countries, doctors
prescribe taking into account the chemical entity, and for them, both types of drugs are
therapeutically equivalent. Alternatively, we could think that drugs are dispensed by
pharmacists that take into account the chemical entity of the drugs. Both situations fit
well within the framework of the model. Type α physicians are loyal to the innovation,
although they may also prescribe the off-patent drug or a generic drug. The remaining
doctors take into account both the total perceived quality and the prices, and prescribe
the drug for which patients’ net utility is higher. We assume that they prescribe generic
drugs instead of the off-patent drug for equal prices. They prescribe the line-extension
if it provides a higher net utility. Net utility when the line extension is prescribed is
given by θs1 − p1 = θ(1 + k) − p1, where p1 is the price of the line extension. For
generic drugs, the net utility is θsi − pgi = θ − pgi , where pgi is the price for the
generic drug of firm i . When the off-patent drug is prescribed, the net utility is θ − pb,
where pb is the price of the off-patent drug. All physicians prescribe as long as the
net utility is non-negative.11
We consider a two-stage game. In the first stage, firm 1 decides the level of inno-
vation k. In the second stage, firms set their prices. We assume that firm 1 acts as a
Stackelberg leader and chooses its prices (p1, pb) first.12 The remaining firms, tak-
ing as given the level of innovation k and firm 1′s prices decide simultaneously their
prices pgi . We solve the game by backward induction, and find the subgame perfect
equilibrium.
Our goal is to characterize the equilibrium prices and the equilibrium level of inno-
vation. Note that, in equilibrium, the price of the line extension p1 must be higher than
both the price of the off-patent drug and the price of the generic drugs. If p1 ≤ pgi
for any i , firm i has incentives to lower its price as otherwise, it would end up with
zero demand. If p1 ≤ pb, firm 1 can increase its profit by increasing p1.
10 These physicians have been prescribing the off-patent drug during patent protection, and inertia makes
them keep on prescribing the same drug improved with the innovation (the line-extension). See Coscelli
(2000).
11 Based on the 1989 National Ambulatory Medical Care Survey for the US, Hellerstein (1998) points out
that almost all physicians prescribe both brand-name drugs and generic drugs, although some physicians
tend to prescribe more often brand-name drugs while others prescribe generic drugs instead.
12 From a theoretical point of view, the decision on prices could have been modelled as a simultaneous
move game. However, in real world, pharmaceutical firms often introduce the line extension previously to
the generic entry to shift demand through loyalty. So, the choice of Stackelberg leadership seems to be a
good approximation to real world. Kong (2009), Ferrara and Kong (2008) and Frank and Salkever (1992)
also model competition between brand-name drugs and generics as a sequential price-setting game.
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3 The determination of the equilibrium prices
3.1 The second stage subgame
Given k and (p1, pb), the firms producing generic drugs simultaneously decide their
prices. As all the generics drugs are equivalent, price competition drives their prices to
zero, the marginal cost, for all k and (p1, pb). Firm 1, taking the level of innovation as
given, set its prices (p1, pb) to maximize its profits taking into account that the price of
the generic drugs is equal to zero. Firm 1 will set pb equal to zero.13 As the off-patent
drug is considered to be equal to the generic drug by both types of physicians, firm
1’s profits from the sales of the off-patent drug are equal for any pb. If pb > 0, the
off-patent drug is not sold, and the profits are zero. Likewise, if pb = 0, the off-patent
drug is sold but the profits are zero. So, the relevant problem for firm 1 is to determine
the price of the line extension p1 that maximizes its profits.
Let us first derive the firm 1’s demand function for the line extension. As the price
of the generic drugs is zero, the consumer indifferent between the line extension and
the generic drug has a severity of illness θˆ that satisfies:
θˆ (1 + k) − p1 = θˆ
Therefore, θˆ = p1
k
. If the consumer with a severity of illness θˆ obtains a non negative
net utility (θˆ (1+k)− p1 ≥ 0), he buys (is prescribed) the line extension, and so do all
consumers with a higher severity of illness. All physicians prescribe the line extension
to these patients. Let θ˜ = p1
1 + k be the severity of illness of the consumer indifferent
between the line extension and not buying. Note that θˆ > θ˜ .
When p1 < k, it follows that θˆ is lower than 1 and firm 1, on the one hand, sells
to all consumers whose severity of illness is greater or equal to θˆ . Thus, its demand
is 1 − θˆ , as both types of physicians prescribe the line extension. These consumers
obtain a strictly positive net utility. On the other hand, there are consumers (those with
severity of illness between θ˜ and θˆ ) that would obtain a higher net utility consuming
the generic drug, although their net utility is also positive if they are prescribed the
line extension. Therefore, a proportion α of physicians (physicians that do not com-
pare prices) prescribe the line extension to these consumers, and firm 1’s demand is
α(θˆ − θ˜ ). Then, firm 1’s total demand is 1 − θˆ + α(θˆ − θ˜ ). When p1 ≥ k, it follows
that θˆ ≥ 1. In this case, firm 1’s total demand is given by α(1− θ˜ ): the line extension is
only prescribed by the loyal physicians as long as patients’ net utility is non-negative.
The demand for the line-extension is depicted in Fig. 1. The demands for the off-patent
drug and the generics are respectively αθ˜ and (1 − α)θ˜ .
13 Given the assumptions of the model, the price of the off-patent drug must be equal to the price of generic
drugs. Although we have considered a free pricing framework, a possible justification for this price equal-
ization can be found in the reference pricing system in place in most European countries. For example, in
Spain, the reference pricing implies that off-patent drugs are priced similarly to generic drugs.
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Fig. 1 The demand for the line extension
Thus, firm 1’s demand for the line extension is given by:
D1 (p1, α, k) =
{
α(1 − θ˜ ) if p1 ≥ k
1 − θˆ + α(θˆ − θ˜ ) if p1 < k
Firm 1 can follow any of two available strategies. On the one hand, it may choose
a high price such that the line extension is prescribed only by the loyal physicians.
Alternatively, it may choose a lower price such that both types of physicians prescribe
the line extension.
If the line extension is prescribed only by the loyal physicians, the price that max-
imizes firm 1’s profits is the solution to:





s.t. p1 ∈ [k, 1 + k]
It is easy to see that the solution to this problem is p1 = 1 + k
2
if 1 > k. Otherwise,
the solution is p1 = k. Let l1(α, k) denote firm 1’s profits when the line extension
is prescribed only by the loyal physicians. By taking into account the solution to the






if 1 > k
αk
1 + k if 1 ≤ k
(1)
Alternatively, firm 1 can maximize its profits by choosing a price such that θˆ < 1. In
this case, it solves the problem:
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max p1
[













s.t. p1 < k
The solution to this problem is p1 = k(1 + k)
2(1 + k − α) if 2α < 1 + k. Firm 1’s profits
in this interior solution are:
1(α, k) = k(1 + k)
4(1 + k − α) (2)
Which is the best strategy for firm 1? When 2α ≥ 1 + k, the best strategy is to
set a price such that only the loyal physicians prescribe the line extension. When
2α < 1 + k, firm 1 chooses the strategy for which profits are higher. Both strategies
are feasible for parameter values within this range and the firm compares its profits
under both strategies. If 1 > k, we have from (1) and (2):
α(1 + k)
4
 k(1 + k)
4(1 + k − α) if and only if α  k
When k ≥ 1, we have from (1) and (2):
1(α, k) − l1(α, k) =
k(1 + k)





(1 + k)2 − 4α (1 + k − α)]
4 (1 + k) (1 + k − α) > 0
The next Proposition summarizes the equilibrium prices for the line extension based
on the above analysis.
Proposition 1 For a given (k, α), firm 1 chooses a price such that only the loyal
physicians prescribe the line extension if α > k. If α ≤ k, the price for the line exten-
sion is such that both types of physicians prescribe it. The equilibrium prices are
p∗1 (α, k) =
k(1 + k)
2(1 + k − α) if α ≤ k and p
∗
1 (α, k) = 0.5 (1 + k) if α > k.
For a given k, if the proportion of loyal physicians is relatively low (below the level
of innovation), firm 1 will prefer to compete for the price-sensitive physicians and
it chooses a price such that they prescribe the line extension to some patients. The
larger k, the higher α must be to find profitable to sell only to the loyal physicians.
Alternatively, for a given α, the level of innovation must be sufficiently high to have
both types of doctors prescribing the line extension. As α grows, the minimum level
of innovation that firm 1 needs to find it profitable to compete for these physicians is
higher. For lower levels of innovation, product differentiation is not large enough and
firm 1 then prefers to exploit the loyal physicians.
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3.1.1 Case α ≤ k
The equilibrium price increases with the level of innovation k and with α. Plugging
the equilibrium prices into the definitions of θˆ and θ˜ yields:
θˆ∗ (α, k) = 1 + k
2 (1 + k − α)
θ˜∗ (α, k) = k
2(1 + k − α)
Note that θˆ∗ (α, k) ∈ (0, 1) and θˆ∗ (α, k) > θ˜∗ (α, k). Firm 1’s customers are mostly
consumers with a high severity of illness. Although the line extension is more expen-
sive than the generic drugs, even the price-sensitive physicians prefer to prescribe the
line extension as the increase in utility derived from the innovative attribute outweighs
paying a higher price. It can be easily shown that θ˜∗ (α, k) grows with k:
d θ˜∗ (α, k)
dk
= (1 − α)
2(1 + k − α)2 > 0
When the level of innovation grows, the valuation of the line extension increases (1+k
is larger) and firm 1 chooses a higher price. The consumer indifferent to being treated
with the line extension or not is now a consumer with a higher degree of illness. On
the contrary, θˆ∗ (α, k) lowers with k:
d θˆ∗ (α, k)
dk
= −α
2(1 + k − α)2 < 0
The higher the level of innovation, the higher the difference between drug prices.
Nevertheless, the severity of illness of the consumer indifferent between the line
extension and the generic drugs is now lower. It can be easily checked that, for a
given k, θˆ∗ (α, k) and θ˜∗ (α, k) grow with α.
We analyze now the effect of k in the sales of the generic drugs. The total sales of
generic drugs G (assuming that loyal physicians prescribe the off-patent drug instead
of a generic drug for equal prices) are given by:
G∗ (α, k) = (1 − α) θˆ∗ (α, k) = (1 − α)(1 + k)
2 (1 + k − α)
For a given α, the larger the level of innovation, the lower the sales of generic drugs
are. For a given k, the sales of generic drugs grow as α gets lower:
dG∗ (α, k)
dk
= − α(1 − α)
2(1 + k − α)2 < 0
dG∗ (α, k)
dα
= − k(1 + k)
2(1 + k − α)2 < 0
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The sales of the line extension are:
D∗1 (α, k) = 1 − θˆ∗ (α, k) + α
(
θˆ∗ (α, k) − θ˜∗ (α, k)
)
= 0.5
The sales of firm 1 do not change with k and α. When the level of innovation
increases, θˆ∗ (α, k) decreases, being now larger the number patients for which both
types of physicians strictly prefer to prescribe the line extension. However, θˆ∗ (α, k)−
θ˜∗ (α, k) decreases, being lower now the number of patients for which the loyal phy-
sicians prescribe the line extension. Both effects cancel each other out leaving the
sales of firm 1 unaltered. When α grows, firm 1, on the one hand, loses some line
extension sales as 1 − θˆ∗ (α, k) decreases but, on the other hand, gains sales as α and
θˆ∗ (α, k)− θ˜∗ (α, k) increases. On aggregate, sales of the line extension do not change.
Note that, for a given k, the sales of firm 1 are equal to those it made before generic
competition. Generic competition initially reduces firm 1’s market share. However,
innovation increases the valuation of the line extension, compensating for the compe-
tition effect.
3.1.2 Case α > k
The price of the line extension increases with k. Plugging the equilibrium prices into
the definitions of θˆ and θ˜ yields:
θˆ∗ (α, k) = 1 + k
2k
> 1
θ˜∗ (α, k) = 0.5
Total sales of generics are 1 − α: all price-sensitive physicians prescribe generic
drugs to all patients. It follows that the generic sales decrease with α. The sales of the
line extension do not depend on the level of innovation, but they increase with α:
D∗1 (α, k) = α
(
1 − θ˜∗ (α, k)
)
= 0.5α
4 The determination of the level of innovation
In the first stage of the game, firm 1, taking into account the second stage equilibrium
prices, chooses the level of innovation k ≥ 0 to maximize its profits, where profits
equal revenues minus innovation costs:
1 (k, α) = p∗1 (α, k) D∗1 (α, k) − C (k) =
⎧⎪⎨
⎪⎩
k (1 + k)
4 (1 + k − α) − C (k) if k ≥ α
α (1 + k)
4
− C (k) if k < α
It is difficult to analyze the determination of the equilibrium level of innovation with
a general cost function. From now on, we will assume that the innovation costs are
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given by C(k) = ck
2
2
with c ∈ (0, 0.25].14 The equilibrium level of innovation will
depend on the parameter c and on the proportion α of loyal physicians.
First, note that the equilibrium level of innovation cannot be below α as the profit







− ck > α
4
− 0.25α = 0
Therefore, the equilibrium level of innovation k∗ (α) solves the following problem:
max 1 (k, α) = k (1 + k)
4 (1 + k − α) −
ck2
2
s.t. k ≥ α (P1)
As the objective function is strictly concave (see Appendix), the solution to this prob-
lem is determined by the first order conditions.
Proposition 2 The equilibrium level of innovation k∗ (α, c) > α ∀ α ≤ 1 and
c < 0.25.
Proof (See Appendix.) 	unionsq
Corollary 1 For c = 0.25, the equilibrium level of innovation k∗ (α) is 1 if α = 1
and k∗ (α) > α if α < 1.
It is interesting to analyze how the equilibrium level of innovation in the interior
solution behaves when the proportion α of loyal physicians changes. We have the
following result:
Proposition 3 Let c ≤ 0.25. Then, ∃ α∗ (c) ∈ (0, 1) such that the equilibrium level of
innovation k∗ (α, c) grows with α for α < α∗ (c) and decreases with α for α > α∗ (c).
Furthermore, α∗ (c) grows with c.
Proof (See Appendix.) 	unionsq
Figure 2 depicts the equilibrium level of innovation.15 As it can be seen, the equilib-
rium level of innovation k∗ (α) exhibits an inverted U-shaped behavior with respect to
α. There is a trade-off between the equilibrium level of innovation and the proportion
of loyal physicians.
The equilibrium level of innovation can be larger if the proportion α of loyal phy-
sicians decreases. For this to happen, the requirement is a sufficiently large α (above
14 For this parameter range, firm 1 competes for the price-sensitive physicians in the second stage, and
in equilibrium, these physicians prescribe the line-extension to some patients. This situation is the one
empirically relevant as Hellerstein (1998) points out. For higher values of c, the profit function 1 (k, α)
has two local maxima but we have not been able to find analytically the global maximum. For low values
of c, however, it is possible to characterize the global maximum. So, we have focused on this range of c to
illustrate the determination of the equilibrium level of innovation.
15 It can be shown that α∗ (c) > 0.5. A proof is available from the authors upon request.
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Fig. 2 The equilibrium level of
innovation
α∗ (c)). Intuitively, when α decreases within that range, firm 1 increases the level
of innovation and the price. Note that its sales do not change. Firm 1 increases the
degree of product differentiation to reduce competition. When all physicians are loyal
(α = 1), firm 1 does not need a high level of innovation as it would be the case if some
physicians were price-sensitive. Product differentiation is less important and firm 1
chooses a relatively low level of innovation as innovation is costly. As α decreases, firm
1 increases the level of innovation. Now, there are some price-sensitive physicians,
and product differentiation becomes important. Firm 1 invests in innovation to soften
competition, increases the price of the line extension and some patients are prescribed
the line extension by the price-sensitive physicians. This pattern of behaviour holds
as long as the proportion of loyal physicians remains above α∗ (c).
However, for low values of α (below α∗ (c)), as α decreases, the equilibrium level
of innovation is lower. In this case, the captive market is not large enough to make
higher levels of product differentiation profitable. Intuitively, when all physicians are
price-sensitive (α = 0), firm 1 launches the line-extension with a positive level of
innovation to differentiate the product. Otherwise, its profits would be zero. As all
physicians prescribe (at least, to some patients) the line extension and innovation
is costly, the equilibrium level of innovation is relatively low. As α grows, firm 1
increases the level of innovation and the price of the line extension to compensate
for the fewer price-sensitive physicians and to exploit the loyal ones. Although loyal
physicians are captive and would prescribe the line extension at a higher price even for
the same level of innovation, they also prescribe it if both the price and the innovation
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are larger. Let us suppose that there were some physicians loyal to the innovation
(α strictly positive) and that the firm kept the same level of innovation as before. Now,
the price of the line extension would be higher as α is larger. Although sales from
price-sensitive physicians would be lower, aggregate revenues would be higher and,
consequently, profits would be larger as innovation costs remain constant. However,
this is not a profit-maximizing strategy as it does not take into account the effect on
profits due to a change in the level of innovation. Profits will be larger if the level
of innovation is modified accordingly. When α is relatively low, both the price and
the level of innovation increase, although the demand for the line-extension from the
price-sensitive physicians does not change too much. Proportionally, the increase in
price is larger than the increase in k. As most of the physicians are price-sensitive, the
firm cannot afford to lose a large amount of sales, and the patient indifferent between
the line-extension and the generic drugs has now a severity of the disease slightly
larger than before. On the one hand, revenues from the prescriptions by the loyal phy-
sicians increase while revenues from the prescriptions from the price-sensitive physi-
cians decrease. On aggregate, total revenues are higher. On the other hand, innovation
costs are larger. Overall, increasing the level of innovation is optimal from a profit-
maximization perspective. The firm needs to balance k and the price of the line exten-
sion to modify the demands from both type of physicians in such a way that profits are
maximized. This pattern of behavior holds as long the proportion of loyal physicians
remains below α∗ (c).
5 Welfare analysis and public policy
In this section, we characterize the level of innovation that maximizes social welfare
and discuss the welfare effects of public policies that reduce the proportion of loyal
physicians. Social welfare is defined as the sum of consumers’ surplus and firms’
profits minus the cost of the innovation. In the model, pharmaceutical expenses are
equal to firms’ profits and, from a social perspective, they cancel each other out. Thus,
social welfare W (k, α) takes into account the surplus enjoyed by the treated patients
(notice that all the patients are treated) and the costs of the innovation:

























θdθ + α (1 + k)
1∫
0.5
θdθ − C(k) if k < α
where θˆ∗ and θ˜∗ have been defined in Sects. 3.1.1 and 3.1.2 for k ≥ α and k < α
respectively. In the appendix (see Lemma 1) we show that the level of innovation that
maximizes social welfare is above α. Recall that the equilibrium level of innovation
chosen by firm 1 is also above α. A question remains as to whether the level of innova-
tion that maximizes social welfare is above the level chosen by the firm. In the context
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of our model, as it happens in real world, innovation increases product differentiation,
reduces competition and increases revenues for firm 1. So, firm 1 has incentives to
choose a relatively high level of innovation. From a social perspective, a high level of
innovation makes competition be less intense. As a result, the price of the line exten-
sion is higher but the size of the covered market remains unchanged. However, some
of the treated patients benefit from the innovation and enjoy higher levels of utility.
In aggregate, consumers’ surplus increases. From a social perspective, as well as in
the case of the firm, there are incentives to choose a high level of innovation. How-
ever, innovation is costly. Thus, there are two forces pulling in different directions.
The relationship between both levels of innovation will depend on how both firm 1’s
revenues and consumers’ surplus change with innovation.
Proposition 4 The level of innovation that maximizes social welfare ks (α, c) is higher
than the level of innovation k∗ (α, c) chosen by firm 1 ∀ (α, c).
Proof (See Appendix.) 	unionsq
From a social perspective, the firm invests in innovation less than the level that it
would be desirable. From this result, some policy implications arise. Health authorities
can act on α given the relationship between k∗ and α found in the previous section.
Health authorities have traditionally tried to promote generic prescription, not only
to reduce the pharmaceutical expenses, but also because it is perceived that new brand-
name drugs incorporate minor innovations that do not bring about health outcomes
substantially better than those from generic drugs, and brand-name drugs are much
more expensive. Within the framework of our model, the promotion of generic pre-
scription is formally equivalent to a reduction in α, and, a priori, it is not clear if this
policy is socially desirable.
Proposition 5 For α ∈ [α∗(c), 1], social welfare decreases with α if
1 + k∗(α, c) − α (1 + 2k∗(α, c)) ≥ 0. For α ∈ [0, α∗(c)], social welfare increases
with α if 1 + k∗(α, c) − α (1 + 2k∗(α, c)) ≤ 0.
Proof (See Appendix.) 	unionsq
When the level of loyal physicians is sufficiently high, policies that reduce loyalty
are desirable as they increase social welfare. However, these policies can also be coun-
terproductive when the proportion of loyal physicians is relatively low. In this case,









positive and the sign of
dW
dα
is ambiguous. If the direct effect of α dominates the
indirect effect in welfare through k∗, then reductions in α would lead to higher levels
of welfare. Otherwise, welfare would be smaller, and the correct policy would be to
encourage loyalty.
6 Conclusions
In this paper, we have considered a model of product differentiation applied to a
pharmaceutical market with n + 1 firms. In particular, we have analyzed how a
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manufacturer of a brand-name drug whose patent is close to expiration decides the
degree of product differentiation of a line extension through innovation before it faces
generic competition. Decisions on innovation and prices are taken within an environ-
ment characterized by loyalty to innovative drugs, where some physicians prescribe
first the line extension while others base their prescribing decisions on efficiency
considerations. We have considered a game with two stages. In the first stage, the
brand-name drug manufacturer decides the level of innovation. In the second stage,
all firms play a sequential pricing game, where the brand-name drug firm acts as a
Stackelberg leader. Depending on the level of innovation and the degree of loyalty,
we have found two equilibria in the pricing game. For high enough levels of innova-
tion, it is optimal for the incumbent firm to compete for the price-sensitive physicians.
However, for levels of innovation lower than the degree of loyalty, such firm prefers
to exploit the loyal physicians and charges the higher monopoly price.
Regarding the level of innovation, we have characterized the equilibrium level of
innovation and analyzed how it changes with the proportion of loyal physicians. We
find that the equilibrium level of innovation exhibits an inverted U-shaped behavior
with respect to the proportion of loyal physicians. For high levels of loyalty, the equi-
librium level of innovation grows when loyalty is reduced. Alternatively, for low levels
of loyalty, the equilibrium level of innovation decreases when loyalty is reduced.
From a social perspective, the firm chooses a level of innovation that is too low.
When the proportion of brand-loyal physicians is sufficiently high, we find that public
policies that reduce loyalty are socially desirable. However, these policies can have a
negative effect on social welfare if the proportion of loyal physicians is relatively low.
In this case, the right policy would be to promote loyalty.
The basic model can be used to analyze several extensions. We have implicitly
assumed that the patients pay the full price of drugs. An extension of the model would
be to introduce a co-payment system and analyze its relationship with the level of
innovation. Co-payment would affect the patient’s net utility, but qualitatively, the
analysis would not be very different. We have also considered that pricing decisions
are taken sequentially. Another possible extension could consist of carrying out the
analysis when pricing decisions are taken simultaneously. We have also assumed a
deterministic innovation process to simplify the analysis. In reality, the outcome of
the innovation effort is random. While considering stochastic innovation outcomes
adds realism to the model, it also complicates its analytical tractability. The model
can be used to analyze also the marketing decisions that endogenize the proportion of
loyal physicians as pharmaceutical firms devote an important proportion of their sales
revenues to marketing activities to generate loyalty to their products.
We have carried out our analysis within a framework of free pricing. In many
European countries, pharmaceutical markets are highly regulated and a reference pric-
ing system operates. The introduction of such a system in our model would not bring
about qualitatively different results. If the reference pricing system is based on bio-
equivalence principles (as in Spain), the off-patent drug and the generics would be
subject to such a system, but the line extension would remain out of it. Price competi-
tion would drive the prices of the off-patent drug and the generics to zero and the line
extension would be priced freely, as in our model. If the reference pricing system is
based on therapeutical equivalence principles (as in Germany), besides the off-patent
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drug and the generics, line extensions that incorporate low levels of innovation would
likely be also subject to such a system, and the results of our model could change. We
hope to explore these issues in further research.
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncom-
mercial License which permits any noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
Appendix
Concavity of the profit function of firm 1





(1 + k)2 − α (1 + 2k)






2 (1 + k − α)3 − c < 0
Proof of Proposition 2 The Lagrangian function for problem P1 is:
L = k (1 + k)
4 (1 + k − α) −
ck2
2
+ λ1 (k − α)
where λ1 is the Lagrange multiplier. The first order conditions are:
dL
dk
= (1 + k)
2 − α (1 + 2k)
4 (1 + k − α)2 − ck + λ1 = 0 (A.1)
plus the restrictions and the complementary slackness conditions. In the solution, the









1 + α (1 − α) − 4cα
4
> 0 ∀α ∈ [0, 1] if c < 0.25
Therefore, ∀α ∈ [0, 1] and c < 0.25, the solution to the optimization problem is
interior: k∗ (α, c) > α 	unionsq





1 + k∗ (α, c)]2 − α (1 + 2k∗ (α, c)) = 4ck∗ (α, c) [1 + k∗ (α, c) − α]2 (A.2)
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Differentiating this expression with respect to α yields:
dk∗ (α, c)
dα
= 1 + 2k
∗ (α, c) − 8ck∗ (α, c) [1 + k∗ (α, c) − α]







1 + 2k∗ (1, c) − 8ck∗ (1, c)2
2k∗ (1, c) [1 − 6ck∗ (1, c)]
where k∗ (1, c) is the equilibrium level of innovation for α = 1. From (A.2), it follows






α=1 = −4c < 0
It remains to shows that
dk∗ (α, c)
dα





1 + 2k∗ (0, c) − 8ck∗ (0, c) [1 + k∗ (0, c)]
2 [1 + k∗ (0, c)] [1 − 2c (1 + k∗ (0, c)) − 4ck∗ (0, c)]
where k∗ (0, c) is the equilibrium level of innovation for α = 0. From (A.2), it follows












|α=0 > 0 and dk
∗ (α, c)
dα
|α=1 < 0. Therefore, there exists a value
α∗ (c) ∈ (0, 1) such that dk
∗ (α, c)
dα
= 0. From (A.3), it follows:
1 + 2k∗ (α∗ (c) , c) − 8ck∗ (α∗ (c) , c) [1 + k∗ (α∗ (c) , c) − α∗ (c)] = 0
Differentiating with respect to c yields:
dα∗ (c)
dc
= 1 + k




Lemma 1 From a social perspective, the equilibrium level of innovation must be
above α.
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Proof It suffices to show that the social welfare function is strictly increasing for
k < α and that ∂W
∂k |k=α > 0. When k < α, social welfare can be written as:
W (k, α)|k<α = 3αk
8











This expression is strictly positive for all k < α and c ≤ 0.25. When k ≥ 0.5α, social
welfare is:





+0.5 (1 + k)
(







− kα (1 − α)









− ck − α(1 − α)
8 (1 + k − α)4
[




− ck − α(1 − α) (1 − 2k)








− cα − α(1−α) (1−2α)
8
= 3 − 8cα − α (1 − α) (1−2α)
8









Proof of Proposition 4 Recall that both ks (α, c) and k∗ (α, c) are above α. In partic-
ular, k∗ (α, c) satisfies:
∂1
∂k
= 0 ⇔ (1 + k
∗(α, c))2 − α(1 + 2k∗(α, c))
4 (1 + k∗(α, c) − α)2 = ck
∗(α, c) (A.6)
and ks (α, c) satisfies:
∂W
∂k
= 0 ⇔ 3
8
− α(1 − α) (1 − 2k
s(α, c))
8 (1 + ks(α, c) − α)3 = ck
s(α, c) (A.7)
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It suffices to show that
∂W
∂k
∣∣k=k∗(α,c) > 0. From (A.5) and (A.6), the derivative of







− (1 + k
∗(α, c))2 − α(1 + 2k∗(α, c))
4 (1 + k∗(α, c) − α)2 −
α(1 − α) (1 − 2k∗(α, c))





− α(1 − α)
4 (1 + k∗(α, c) − α)2 −
α(1 − α) (1 − 2k∗(α, c))
8 (1 + k∗(α, c) − α)3
= 1
8
− α(1 − α)(3 − 2α)
8 (1 + k∗(α, c) − α)3
As 1 + k∗(α, c) − α > 1, it follows that α(1 − α)(3 − 2α)
(1 + k∗(α, c) − α)3 < 1 and therefore
∂W
∂k
∣∣k=k∗(α,c) > 0. 	unionsq














α ∈ [α∗(c), 1]. From Proposition 3, dk∗(α)
dα










< 0. From (A.4), the effect of α in social welfare, keeping





8 (1 + k∗(α, c) − α)3
[(
1 + k∗(α, c) − α) (1 − 2α) + 2α (1 − α)]
= − k
∗(α, c)
8 (1 + k∗(α, c) − α)3
[
1 + k∗(α, c) − α (1 + 2k∗(α, c))] (A.9)
When 1 + k∗(α, c) − α(1 + 2k∗(α, c)) ≥ 0, it follows from (A.8) that dW
dα
< 0.
If 1 + k∗(α, c)−α(1 + 2k∗(α, c)) < 0, the effect of α in social welfare is ambiguous.
Let α ∈ [0, α∗(c)]. From Proposition 3, dk
∗(α)
dα










> 0. From (A.9), it is required that 1 + k∗(α, c) − α(1 +
2k∗(α, c)) ≤ 0. If 1+k∗(α, c)−α(1+2k∗(α, c)) > 0, the effect of α in social welfare
is ambiguous. 	unionsq
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